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Abstract
Background: Notwithstanding progress in recent years, a safe, an effective and affordable malaria vaccine is not 
available yet. Ookinete-secreted protein, Plasmodium vivax von Willebrand factor A domain-related protein (PvWARP), is 
a candidate for malaria transmission-blocking vaccines (TBVs).
Methods: The PvWARP was expressed in Escherichia coli BL21 using the pET-23a vector and was purified using Ni-NTA 
affinity chromatography from a soluble fraction. Polyclonal antibody was raised against rPvWARP and transmission 
blocking activity was carried out in an Anopheles stephensi-P. vivax model.
Results: Expression of full length of PvWARP (minus signal peptide) expression showed a 35-kDa protein. The purified 
protein was recognized by mouse polyclonal antibody directed against rPvWARP. Sera from the animals displayed 
significantly a blocking activity in the membrane feeding assay of An. stephensi mysorensis.
Conclusions: This is the first report on P. vivax WARP expression in E. coli that provides an essential base for 
development of the malaria TBV against P. vivax. This may greatly assist in malaria elimination, especially in the oriental 
corner of WHO Eastern Mediterranean Regional Office (WHO/EMRO) including Afghanistan, Iran and Pakistan.
Background
Plasmodium vivax is responsible for 25-40% of annual
cases of malaria especially in parts of Latin America and
Asia [1]. Drug resistance in P. vivax is spreading and vivax
malaria has been considered lethal in a similar way to
severe falciparum malaria [1-3], challenging the concept
that P. vivax malaria as 'benign' [4]. Therefore, the devel-
opment of new control strategies such as a safe and an
effective malaria vaccine is expected to play an important
role in controlling P. vivax malaria [5].
Based on the life cycle stages, malaria vaccines have
focused on candidate target antigens on asexual and sex-
ual stages of the parasite [6]. A transmission-blocking
vaccine (TBV) targeting the parasite's sexual stages aims
at interfering and/or blocking pathogen development
within the vector and halting transmission to the non-
infected vertebrate host [7,8]. Most TBV candidate tar-
gets have been focused on gametocytes, gametes, zygotes
or ookinetes [9]. Li et al., [10] concluded that ookinete
micronemal proteins, chitinase 1 (CHT1), circumsporo-
zoite protein/thrombospondin-related anonymous pro-
tein-related protein (CTRP) and WARP (von Willebrand
factor A domain-related protein) may constitute a general
class of malaria TBV candidates. warp is expressed in late
ookinetes and early oocysts [11,12]. This gene had limited
polymorphism in clinical isolates of Plasmodium falci-
parum collected from a wide variety of geographical
regions [13]. Similarly, the first large-scale survey, con-
ducted on pvwarp polymorphism in both temperate and
tropical P. vivax field isolates in Iran, showed that there is
a limited polymorphism in this gene [14]. Looking to its
biological activity, it was shown that mouse polyclonal
antisera raised to recombinant PfWARP had nearly a
complete (97-100%) transmission-blocking activity of P.
falciparum to Anopheles gambiae mosquitoes [10].
Accordingly, it seems that a parallel study on PvWARP
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based TBV.
P. vivax is a dominant malaria parasite outside Africa.
In 2008, 11,333 cases of malaria were reported from Iran,
which 10,240 (> 90%) were P. vivax, 894 P. falciparum and
the remaining 195 were mixed infection (the Ministry of
Health, 2008). On the other hand, An. stephensi is an
important oriental malaria vector, prevalent in much of
the Indo-Pakistan subcontinent and countries around the
Persian Gulf [15]. In Sistan and Baluchistan province
located in southeastern part of Iran, An. stephensi myso-
rensis is the most dominant biological form [16,17],
which readily attacks man and it has been shown that
15.7% were positive for human blood [18-20]. RAPD and
rDNA-ITS2 molecular markers revealed that in Iran, An.
stephensi could be considered as a single species with dif-
ferent biological and ecological forms in various zoogeo-
graphical zones [15].
This study aimed to determine the possibility of devel-
oping an anti-PvWARP in a An. stephensi-P. vivaxmodel
that could be applied as a malaria TBV in the oriental cor-
ner of EMRO including Afghanistan, Iran and Pakistan.
Therefore, this study reports, for the first time, the effi-
cient and successful cloning and expression of full length
PvWARP (minus signal peptide), an ookinete-secreted
TBV candidate. Recombinant PvWARP elicits potent
malaria transmission-blocking antibodies in mice and the
blocking of P. vivax sporogonic cycle in An. stephensi
mysorensis was evaluated by these antibodies.
Methods
Cloning and sub-cloning of PvWARP
Molecular epidemiology study in the tropical and tem-
perate P. vivax isolates revealed that pvwarp had a limited
polymorphism with two non-synonymous substitution
[13]. Therefore, the representative of haplotype II of the
Iranian P. vivax isolates ([GenBank: FJ170315]) was used
as a template for the amplification of full-length
PvWARP, amino acid positions 24-295, using 5'...GTGG-
GATCCAAAATAAACCTTGTGTCGC...3' and
5'...ACCCAAGCTTGTCCGTAGAGTCGCTGTC...3' as
forward (EPvWF) and reverse (EPvWR) primers. The
bold sequences show BamHI and HindIII restriction
sites, respectively. The amplification profile was as fol-
lows: denaturation at 95°C for 1 min, followed by 30
cycles of annealing at 60°C for 1 min and extension at
72°C for 1 min with 10 min extra extension time in the
last cycle. The amplified fragment was cloned into
pGEM-T Easy vector (Promega, USA) after purification
from the gel. Selection of the transformed clones was car-
ried out on the Luria-Bertani (LB) agar medium contain-
ing 100 μg/ml ampicilin, 1.5 mM isopropyl-β-d-
thiogalactopyranoside (IPTG) and 0.04% X-gal. Positive
clones were confirmed by plasmid isolation followed by
digestion with EcoRI and sequencing the cloned frag-
ments. The insert was excised with restriction enzymes
BamHI and HindIII. After ligation of the insert to the
BamHI-HindIII sites of vector pET-23a (Qiagen, Ger-
many) containing poly-histidine tag at the C-terminus,
the construct, pET-23a+PvWARP was transformed into
competent E. coli DH5α cells. The recombinant clones
were selected on 25 μg/ml chloramphenicol and ampici-
lin plates. The open reading frame was confirmed by
sequencing and this construct was then used to trans-
form E. coli BL21 (PlysS) for expression.
Expression and purification of recombinant PvWARP
The transformed cells were grown overnight in LB
medium containing 25 μg/ml chloramphenicol and 100
μg/ml ampicilin with shaking (150 rpm) at 37°C until the
OD at 600 nm of culture reached 0.6-0.7. The cells were
incubated with 1 mM IPTG (Sigma, USA) and grown at
37°C for four hours . Then they were harvested by centrif-
ugation for 10 min and kept in -80°C until use. The frozen
pellet was dissolved in denaturation buffer including 6 M
guanidine thiocyanate, 20 mM Tris-HCl, 500 mM NaCl,
20 mM immidazol and 1 mM PMSF, pH 7.9. The cells
containing PvWARP inclusion bodies were lysed on ice
by 15 cycles of sonication (Ultraschallprozessor; Ger-
many), each cycle consisted of 20 s pulses with 40 s inter-
vals. To remove cellular debris, the bacterial lysate was
centrifuged at 10,000 rpm at 4°C for 15 min. The super-
natant was incubated with Ni2+-nitrilotriacetic acid aga-
rose resin (Ni-NTA Agarose, Qiagen, Germany) at 4°C
for 2 h and the resin was transferred into a column. After
washing with 6 M urea, 20 mM Tris-HCl, 500 mM NaCl
and 30 mM immidazol (pH 7.9), the protein was eluted as
0.5 ml fractions with an elution buffer containing 8 M
urea, 50 mM Na2HPO4, 300 mM NaCl, 250 mM immida-
zol (pH 7.9). The fractions containing PvWARP were
desalted in PBS with Econo-Pac 10DG columns (BioRad,
USA) according to the manufacture's manual. All eluates
were analyzed by SDS-PAGE on 12% gels under reducing
conditions. Finally, the protein concentration was esti-
mated using the Bradford assay. Immunoblotting was car-
ried out by standard protocols, using by both anti-His
antibody (Qiagen, Germany) and the sera of mice immu-
nized with rPvWARP.
Antibody production
Male BALB/c mice (n = 6), six to eight weeks old, were
immunized with 50 μg of PvWARP emulsified in com-
plete Freund's adjuvant (CFA) (Sigma, Germany). Then, it
was followed by two booster injections (twice at 3-week
intervals) with 25 μg of protein emulsified in incomplete
Freund's adjuvant. Mice in the control group (n = 6) were
immunized with the sera adjuvant formulations in PBS.
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trol group.
Membrane feeding assay
The antibody activity against development of sexual stage
of P. vivax was examined using the infected blood of vol-
unteer patients in Sistan and Baluchistan province, Iran
where vivax malaria is endemic. First, local An. stephensi
mysorensis insectarium colony was established in Iran-
shahr and Chabahar districts, the cities located in south-
eastern part of Iran. Larvae were reared in bowls at a
density of 300 larvae/500 ml of water. The pupae were
transferred to 50 × 50 × 50 cm cages made of muslin cloth
to harbor adults with free mating. All mosquitoes were
maintained at 28 ± 2°C temperature and 70 ± 10% relative
humidity with 12:12 h light and dark photoperiods
adjusted by fluorescent lighting. During rearing, the adult
mosquitoes were fed on 5% glucose solution and the
females on rabbit blood. Nulliparous female mosquitoes
were starved for 12-18 hours before feeding on a blood
meal containing P. vivax gametocytes and anti-PvWARP.
Blood containing P. vivax gametocytes was collected
from local volunteer malaria patients who were attended
at local clinics in Chabahar district. In case, the volunteer
patients were chosen for interview and in order to avoid
any intervention of drug against development of sexual
stages of the parasite, only those patients who had not
previously taken any anti-malarial drugs for the current
infection were chosen as donors. The gametocyte density
of the isolate of P. vivax was 47 and 75 gametocytes/200
White Blood Cells. In addition, an informed consent was
obtained from all individuals who were participated in
this study, and an ethical approval was obtained from
Pasteur Institute of Iran and Tehran University of Medi-
cal Sciences. Then the patients were followed up for
treatment by local health services personnel.
Female An. stephensi mosquitoes were fed on mem-
brane feeders (constructed from aquarium hitter, beaker
and parafilm) containing 200 μl of P. vivax-infected blood
plus 70 μl of antisera and normal human sera (donor
blood group: O+) for 60 min. Non-engorged mosquitoes
were removed, and engorged mosquitoes were main-
tained in double cages with 5% glucose at 28 ± 2°C and
80% relative humidity. Experimental and control groups
(PBS+FA, NMS and gametocyte containing blood) were
infected in parallel with two independent field isolates of
P. vivax originated from malaria patients. Mosquito
midguts were dissected in PBS 12-14 days after blood
meal, stained with mercurochrome 2% and oocysts were
enumerated to calculate the transmission blocking activ-
ity in different groups.
Statistical analysis
Statistical analysis was performed using the Mann-Whit-
ney U test to compare differences in geometric mean
oocyst density and the proportion of mosquitoes infected
between groups was carried out by using SPSS software.
Results
Cloning and expression of pvwarp fragment
The sequence of PvWARP lacking the N-terminal signal
sequence amino acid residues 1-23 was amplified from P.
vivax genomic DNA ([GenBank: FJ170315]) [13]. There
were two non-synonymous substitutions at the amino
acids T83 and R177 in comparison with Sal I ([GenBank:
XM001608555]), replacing with A and S, respectively.
The G/C and A/T contents of pvwarp sequence were
48.99% and 51.01%, respectively. Following sub-cloning
the fragment into the expression vector pET-23a (Figure
1A), PvWARP was expressed in E. coli BL21 cells (Figure
1B). An optimization of the expression in different times
was used to yield soluble proteins. We modified expres-
sion strategy by growing the cells in LB medium at 37°C
and induction with 1 mM IPTG for 4, 6 and 24 h (Figure
1B). Highly efficient induction of a 35-kDa protein was
performed at 4 h after induction (Figure 1B). A spot with
PvWARP and a molecular weight close to the estimated
values calculated for PvWARP (35 kDa) was revealed in
SDS-PAGE gel after induction but absent in control (Fig-
ure 1B).
Protein purification and antibody production
The purification protocol was optimized for PvWARP
and recombinant protein was purified using Ni-NTA-
Agarose beads (Qiagen, Germany) by elusion using imi-
dazole. The yield of purified PvWARP in different inde-
pendent purifications varied between 300-500 μg/ml of
purified solution. Western blot analysis which was car-
ried out with PvWARP showed the recognition of a single
band around 35 kDa.
To assess the immunogenicity of purified protein with
CFA, six mice were vaccinated with rPvWARP and tested
the resultant sera. When a single run of Western blot
analysis was carried out, the sera from all mice vaccinated
with rPvWARP recognized the immunogen. The sera
from control mice vaccinated with adjuvant and non-vac-
cinated mice showed no antibody response (Figure 1C).
Transmission blocking assay
Membrane feeding experiments were performed to
assess the functionality of the immunized sera transmis-
sion blocking activity in An. stephensi mosquitoes. The
result of infecting Anopheles were led to the development
of P. vivax oocysts only in midgut of mosquitoes artifi-
cially fed on NMS, PBS+FA and infected blood (Figures
2). The ratios of mosquitoes supporting oocyst in their
midgut were about 21-23% in control group that fed on
gametocyte-infected blood from field isolates. The pres-
ence of oocyst in controls including PBS+FA and NMS
was about 16% to 21%. Antisera to rPvWARP showed a
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However, An. stephensi mosquitoes fed with P. vivax
gametocyte-infected blood containing anti-rPWARP
developed no oocyst in their midgut. Geometric mean
oocyst numbers per midgut in different control groups
ranged between 1.15 and 1.44 (Table 1).
Discussion
The current study reports, for the first time, the cloning
and expression of rPvWARP, ookinete-secreted protein
from field collected P. vivax isolates. The anti-recombi-
nant protein (anti-PvWARP), which is produced in the
mice immunized with Freund's adjuvant formulation,
showed transmission-blocking activity.
Continuous reduction of malaria transmission by using
vaccines targeting sexual stage in malaria transmission
will be essential for achieving the global action plan goal
of Roll Back Malaria, elimination and perhaps eradication
of this disease from various endemic countries. To assess
transmission blocking activity, all previous studies were
Figure 1 Cloning, expression and characterization of PvWARP. A) Digestion result of the extracted plasmid (pET-23a) from DH5a by using BamHI 
and HindIII restriction enzymes on 1.5% agarose gel. M: DNA molecular marker. B) Optimization of PvWARP expression in pET-23a at E. coli strain BL21 
host in 4, 6 and 24 hours after induction. B: before induction, M: protein molecular weight maker (kDa). C) Western blotting of polyclonal antibody for 
PvWARP. Purified protein was blotted on nitro cellulose membrane and stained by diaminobenzidine; lanes 1: negative control (mice without any 
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human or other non-human malaria parasites. However,
in this study, An. stephensi-P. vivax model was employed
to study the efficacy of raised antibody against PvWARP
over field conditions. An. stephensi is the major vector of
human malaria outside Africa (Middle East and South
Asia), and belongs to the same subgenus as Anopheles
gambiae. On the other hand, P. vivax as a neglected para-
site is predominant cause of human malaria in the Middle
East, central and southeast Asia and South America [21].
In addition, results of parasite development in the cur-
rent study is in agreement with report of Basseri et al.
[17] about the competency of An. stephensi mysorensis
strain to P. vivax in the same area that from all infected
mosquitoes with P. vivax, the overall number of mosqui-
toes supporting oocysts in their midgut was 21.9%. In this
Figure 2 Inhibitory effect of anti-rPVWARP on infectivity of An. stephensi to P. vivax. The percentage of engorged, dissected and supporting 
oocyst in the midgut of An. stephensi mysorensis mosquitoes reported as the mean of two different field isolates. NMS: control group mosquitoes fed 
by infected blood containing normal mouse sera, PBS+FA: control group mosquitoes fed by infected blood containing sera of mouse immunized by 
PBS and Freund's adjuvant, IB: control group mosquitoes fed only by infected blood.
Table 1: Effect of anti-rPvWARP sera raised in mouse on P. vivax infectivity to An. stephensi mosquitoes
Experiment Antibody Geometric mean 
no. of oocysts in midgut (range)
No. infected/total 
engorged mosquitoes (% prevalence)
1 Control (Infected blood) 1.43 (0-3) 5/23 (21.74%)
Control (PBS+FA) 1.15 (0-2) 3/18 (16.6%)
Control (NMS) 1.26 (0-2) 5/24 (20.8%)
Anti-PVWARP 0.00 (0-0) 0/28 (0%)
2 Control (Infected blood) 1.43 (0-3) 5/22 (22.73%)
Control (PBS+FA) 1.19 (0-3) 3/19 (15.8%)
Control (NMS) 1.44 (0-2) 5/19 (21.05%)
Anti-PVWARP 0.00 (0-0) 0/23 (0%)
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ferent control groups (NMS, PBS+FA and Infected
Blood) developed the oocyst in their midguts. It seems
that the low number of developed oocyst on midgut of
female mosquitoes is a bottleneck for life cycle of Plasmo-
dium parasites, which may provide more chance for
inhibiting the parasite development using TBV, though
drawing any conclusion needs more robust data and fur-
ther field experiments.
Conclusions
Antigens such as WARP, which is expressed on the sur-
face of mosquito-stage parasites have been postulated as
TBV candidates because it seem not to be under the
selective pressure mediated by the vertebrate immune
system. Consequently, this protein exhibited low levels of
polymorphisms favouring the efficacy of vaccines derived
from a unique antigenic variant. Further, as a certain
types of adjuvants induce reactogenicity in humans [22]
and animal models, the use of other adjuvants to boost
TBV antigen response is a significant issue to be resolved.
Although anti-malarial drugs currently work well against
vivax malaria, a vaccine that targets P. vivax would proba-
bly reduce the transmission rate and parasite density
within local populations which may greatly assist in com-
plete malaria elimination, especially in this oriental cor-
ner of EMRO including Afghanistan, Iran and Pakistan.
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